Apnimed, Inc.'s next confirmed earnings release is scheduled for March 3, 2027.
| Earnings Date | 3/3/2027 |
As of June 30, 2026, Apnimed, Inc. has 39.82M shares outstanding.
| Shares Outstanding | 39.82M |
As of June 30, 2026, Apnimed, Inc. maintains a current ratio of 5.19, meaning it holds 5.2x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 5.19 |
| Quick Ratio | 4.88 |
| Debt / Equity | -45.61 |
These figures are as of the close on November 16, 2026.
| 50-Day Moving Average | 20.29 |
These figures cover the twelve months ended June 30, 2026.
| Gross Profit | 10.87M |
| Pretax Income | 126.11M |
As of June 30, 2026, Apnimed, Inc. holds 172.80M in cash and equivalents against 80.35M in total debt, resulting in a net debt position of -93.21M. Total book value stands at -176.18M, with working capital of 149.19M providing operational flexibility.
| Cash & Cash Equivalents | 172.80M |
| Total Debt | 80.35M |
| Net Debt | -93.21M |
| Equity (Book Value) | -176.18M |
| Book Value Per Share | -4.42 |
| Working Capital | 149.19M |
These figures cover the twelve months ended June 30, 2026.
| Free Cash Flow | -18.11M |
| FCF Per Share | -0.45 |
Over the twelve months ended June 30, 2026, Apnimed, Inc. posted a gross margin of 89.98, reflecting its pricing power and cost economics. The operating margin of -96.89 and net profit margin of 1,042.51 provide insight into operational efficiency.
| Gross Margin | 89.98 |
| Operating Margin | -96.89 |
| Pretax Margin | 1,043.98 |
| Profit Margin | 1,042.51 |